Fig. 7.

Full-length variants of bD1 have improved binding to both the soluble and membrane-bound form of HER2. (A) Each purified antibody was analyzed by ELISA to determine relative binding to soluble HER2-Fc or milk-coated (control) wells. (B) SK-OV-3 cells were incubated with purified antibody and stained with goat-anti-Fc-Alexa Fluor 647, then analyzed by flow cytometry. Control samples were antibody incubated with CHO-K1 cells and SK-OV-3 cells incubated with an irrelevant antibody isotype control.